How long can I take Lorlatinib? Long-term treatment survival and drug resistance

Lorlatinib (Lolatinib) is a third-generation ALKtyrosine kinase inhibitor, mainly used to treat ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC). As a targeted drug, lorlatinib (lorlatinib) has strong brain penetration and higher ability to control drug-resistant mutations, so it is often used clinically for patients after failure of previous treatments. There is no fixed "maximum number of years" for taking lorlatinib. It is usually continued as long as the disease is under control and the patient can tolerate it.

In real clinical practice, some patients have been treated with lorlatinib for more than 2 years or even longer and still maintain good quality of life and stable disease. Research data shows that the median progression-free survival (PFS) of some ALK-positive lung cancer patients who receive lorlatinib (lorlatinib) treatment can reach more than 12 months, and individual patients with good responses can maintain a longer survival period. As long as the drug's efficacy is sustained and no serious adverse reactions or obvious drug resistance occur, patients can usually take it for a long time.

However, like most targeted drugs, long-term use of lorlatinib carries the risk of drug resistance. Some patients may experience tumor progression after a year or more of treatment, often due to new ALK mutations or activation of other pathways. At this time, doctors will evaluate whether lorlatinib (lorlatinib) can continue to be used based on the genetic test results, or switch to other treatment options, such as chemotherapy, immunotherapy, or clinical trial drugs.

Overall, lorlatinib can achieve long-term disease control in some patients with ALK-positive NSCLC, but the duration of efficacy varies from patient to patient. Patients who respond well to the drug and do not experience intolerable side effects can continue taking it for many years. Regular imaging examinations and genetic testing are essential to evaluate efficacy and monitor drug resistance, and can also help to adjust treatment strategies when necessary, thereby maximizing patient survival and improving quality of life.

Reference link:https://www.lorbrena.com/